Medpace: High Order Growth in Clinical Research - Share Price Jump of 16% Towards All-Time High!
Reading Time: 2 minutes
The revenue growth was 17.2% to 707.3 million USD in the second quarter of 2026. Net new order intake increased by 28.2%, providing the company with a predictable base. The annual forecast for 2026 anticipates total revenue of up to 2.89 billion USD. Revenue and Profit Development in the Second Quarter On July 22, 2026, Medpace Holdings Inc. (MEDP) released its financial figures for the second quarter. The company recorded revenue of 707.3 million USD, which represents an increase of 17.2% compared to the same quarter last year. On the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
